Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Parallel, and Active-controlled PhaseⅢTrial
Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Listed as NCT02430350, this PHASE3 trial focuses on Acute Ischemic Stroke and remains completed. Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd., it has been updated 7 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Dec 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu Simcere Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baotou, China , Beijing, China , Cangzhou, China , Changchun, China , Changsha, China , Chengdu, China , Fuzhou, China , Guangzhou, China , Guilin, China , Guiyang, China and 22 more locations